In March 2025, the company announced new designs for a direct-to-customer offering of its Wegovy weight loss drug. The company set up a different pharmacy, known as NovoCare, which would charge prospects $499 monthly for entry to the drug, below 50 percent the cost of the drug via other pharmaceutical distribution networks.[fifty three]Even so, It